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Background and purpose: Despite a strong correlation to severity of AD pathology, the
measurement of medial temporal lobe atrophy (MTA) is not being widely used in daily
clinical practice as a criterion in the diagnosis of prodromal and probable AD. This is
mainly because the methods available to date are sophisticated and difficult to implement
for routine use in most hospitals—volumetric methods—or lack objectivity—visual rating
scales. In this pilot study we aim to describe a new, simple and objective method for
measuring the rate of MTA in relation to the global atrophy using clinically available
neuroimaging and describe the rationale behind this method.
Description: This method consists of calculating a ratio with the area of 3 regions traced
manually on one single coronal MRI slide at the level of the interpeduncular fossa: (1)
the medial temporal lobe (MTL) region (A); (2) the parenchima within the medial temporal
region, that includes the hippocampus and the parahippocampal gyrus—the fimbria taenia
and plexus choroideus are excluded—(B); and (3) the body of the ipsilateral lateral ventricle
(C). Therefrom we can compute the ratio “Medial Temporal Atrophy index” at both sides
as follows: MTAi = (A − B)×10/C.
Conclusions: TheMTAi is a simple 2D-method for measuring the relative extent of atrophy
in the MTL in relation to the global brain atrophy. This method can be useful for a more
accurate diagnosis of AD in routine clinical practice. Further studies are needed to assess
the usefulness of MTAi in the diagnosis of early AD, in tracking the progression of AD and
in the differential diagnosis of AD with other dementias.
Keywords: medial temporal lobe atrophy, biomarker, Alzheimer, mild cognitive impairment, MRI, neuroimaging,
diagnosis
BACKGROUND
Alzheimer’s disease’s (AD) pathology accumulates for years and
may be even decades before it is typically diagnosed (Morris
et al., 1996). Sensitive biomarker techniques may be able to pick
up signs of neurodegeneration presymptomatically. Recently pro-
posed criteria for research purposes for prodromal AD (Sperling
et al., 2011), mild cognitive impairment (MCI) due to AD
(Albert et al., 2011), and probable AD dementia (McKhann et al.,
2011) incorporate evidence of AD pathology including molecular
changes and brain structure and function as supportive biomark-
ers. MRI-based biomarkers are among the supportive evidence
for a diagnosis of early AD and MCI due to AD. By focusing
on cortical regions known to be affected in AD dementia, subtle
but reliable atrophy is identifiable in asymptomatic individuals
nearly a decade before dementia, making this measure a poten-
tially important imaging biomarker of early diagnosis (Dickerson
et al., 2011). Volume losses in the medial temporal lobe (MTL)
region—composed by the hippocampus and the parahippocam-
pal gyrus—and posterior cingulated and orbitofrontal regions
have been observed in AD and confirmed in many studies
(Kesslak et al., 1991; Parnetti et al., 1996; Smith and Jobst, 1996;
de Leon et al., 1997; Jack et al., 1997; Nagy et al., 1999; Bouwman
et al., 2007; Eckerstrom et al., 2010; Jack et al., 2010; Zhang et al.,
2010; Apostolova et al., 2012; Ewers et al., 2012; Leung et al., 2013;
Heister et al.). This leads to a predictable pattern of brain atro-
phy that could be very useful to improve diagnosis and follow
up and help making a better assessment of the neuroprotective
effects of a therapy. The quantification of atrophy in the MTL
(MTA) has been attempted using several different neuroimaging
measurements, including rating scales, linear measurements, and
volumetric methods.
Visual assessment rating scales are quick, and can be
performed on large numbers of scans in a clinical setting, the
disadvantage being that there is a loss of accuracy compared
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with objective analysis and are subjected to interrater variability
(Westman et al., 2011). Some studies found that visual rat-
ing assessment of the MTL gave similar prediction accuracy
to multivariate classification and manual hippocampal volumes
(Ringman et al., 2010; Duara et al., 2013) while others reported
the visual rating assessment failed to detect patients at high risk,
such as people carrying mutations of familial AD and also failed
to detect progression over time (Ridha et al., 2007; Pereira et al.,
2013). In addition, clinical, demographic, and genetic variables
can influence the classification of MTA cut-off scores, leading
to misdiagnosis in some cases. These variables, in addition to
the differential sensitivity and specificity of each cut-off, should
be carefully considered when performing visual MTA assessment
(Scheltens et al., 1992).
Linear measures of brain regions are easy to take using clin-
ically available neuroimaging. Some studies attempted to define
sentinel changes that will allow the use of linear measurements
of the hippocampus or the temporal horn to support clinical
decision making. These studies have yielded variable results, with
sensitivities ranging from 33 to 93% and specificity of approxi-
mately 95% (Dahlbeck et al., 1991; Erkinjuntti et al., 1993; Frisoni
et al., 2002).
Volumetric analysis provides an accurate and detailed measure
of a predetermined circumscribed area or region of interest. For
AD, the most used structure is the whole hippocampus. Some
indices comparing the extent of atrophy in the hippocampus
with the whole brain atrophy are also being described (http://
brainatrophyindices.blogspot.com).Manual volumetry is consid-
ered the gold standard but it has some drawbacks. First it requires
training since the tracer must learn to delineate the hippocam-
pus’s boundaries and anterior- and posterior-limits. Then seg-
mentation of the hippocampus takes approximately 20–30min,
depending on user experience (Soininen et al., 1994; Petrella
et al., 2003), which limits routine clinical use. Some groups auto-
mated segmentation techniques and protocols for multi-atlas
driven automatic segmentation of the hippocampus (Morra et al.,
2008; Brewer et al., 2009; Kovacevic et al., 2009). Results of a
study comparing manual and automated determination of hip-
pocampal volumes in MCI and early AD indicated that these
two methods derived highly correlated results with strong agree-
ment (Shen et al., 2010). Albeit homogenization efforts are under
development (Frisoni and Jack, 2011; Boccardi et al., 2013), the
complexity and diversity of protocols used for volumetry keeps
being a limitation today.
In summary, despite convenience and strong correlation to
severity of AD pathology, MTA is not being used in daily clini-
cal practice for diagnosing prodromal and probable AD yet, as it
is in clinical trials and research studies. This is mainly because the
methods already described lack accuracy (visual methods) or are
not convenient enough to be routinely used by clinicians in busy
departments (volumetric methods).
PURPOSE
In this report we aim to describe a new, objective and simple
2D-method for measuring atrophy of the MTL using clinically
available neuroimaging. We also aim to explain the rationale
behind this method. However, we do not seek to describe here the
validity of this parameter for diagnosing AD since these researches
are being conducted currently and results will be addressed in
future publications.
PROTOCOL DESCRIPTION
This method consists of measuring the area of 3 brain regions
on one single MRI slide and then use these data for calculat-
ing a simple ratio. First, we take the coronal slide at the level of
the interpeduncular fossa on the TIR sequence. Then, regions
are traced manually, simply using the pointer-rule tool of any
software for visualizing DICOM images. As guidelines to draw
structures and boundaries we followed the atlases by Mai et al.
(1997) and Duvernoy (1998). The three areas are: (1) the MTL
region (A), defined in a coronal brain slide as the four-sided
space bordered in its inferior side by the tentorium cerebelli, in
its medial side by the cerebral peduncles, in its upper side by the
roof of the temporal horn of the lateral ventricle and in its lateral
side by the collateral sulcus and a straight-line linking the collat-
eral sulcus with the lateral edge of the temporal horn of the lateral
ventricle; (2) the parenchima within the medial temporal region,
that includes the hippocampus and the parahippocampal gyrus—
the fimbria taenia and plexus choroideus are excluded—(B); and
(3) the body of the ipsilateral lateral ventricle (C) (Figure 1).
Therefrom, we can compute the ratio “Medial Temporal Atrophy
index (MTAi)” at both sides as follows:MTAi = (A – B) × 10/C.
An example is shown in Figure 2.
If we have two MRI studies from different times (1 =
first one, 2 = second one), we can also compute the yearly
rate of MTA as follows: yrMTA = (A2 − B2) − (A1 − B1) ×
120/(#months between MRI studies) and the yearly rate of rel-
ative MTA as follows: (yrMTAr) = (A2 − B2) − (A1 − B1) ×
120/(C2 − C1)× (#months between MRI studies).
EXPRESSING THE MEDIAL TEMPORAL ATROPHY INDEX
When we compute the MTAi we obtain 2 values, one for
each hemisphere. In addition, it is also interesting to com-
pute the median of these 2 values, and the index of asymme-
try (IA). We determine the IA using formula IA = (lMTAi −
dMTAi)/(lMTAi + dMTAi) × 100. Small positive or negative IA
values of magnitude less than ∼ ±3% indicate that there is not
a significant hemispheric asymmetry and the median MTAi can
be used alone as a parameter of the global relative MTA. Higher
IA values indicate significant hemispheric asymmetry and the
median value should not be used alone since it is not a good rep-
resentative value of the extent of relative MTA. Thus, the MTAi
can be presented directly as the absolute right/left MTAi values or
as the median MTAi with the IA (Table 1).
RATIONALE BEHIND THE MEDIAL TEMPORAL ATROPHY
INDEX
The rationale behind this method is based on two premises:
First, AD is a disease affecting the hippocampus, not a disease
of the hippocampus. From a neuropathological point of view
it is evident that that the characteristic pathological changes in
AD begin outside the hippocampus, with development of neu-
rofibrillary tangles in the transentorhinal and entorhinal cortex,
spreading subsequently to the subiculum and CA1 regions of the
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FIGURE 1 | MRI from a patient with MCI with boundaries of the three
areas needed for calculating the Medial Temporal Atrophy index
(MTAi). The section passes through the interpeduncular fosae. The three
areas are: (1) the medial temporal lobe region (A), defined in a coronal brain
slide as the space bordered in its inferior side by the tentorium cerebelli, in
its medial side by the cerebral peduncles, in its upper side by the roof of
the temporal horn of the lateral ventricle and in its lateral side by the
colateral sulcus and a straight-line linking the colateral sulcus with the
lateral edge of the temporal horn of the lateral ventricle; (2) the parenchima
within the medial temporal region, that includes the hippocampus and the
parahippocampal girus (B); and (3) the body of the ipsilateral lateral ventricle
(C).
hippocampus (Jack et al., 1992; Braak and Braak, 1985; Convit
et al., 2000; Kerchner et al., 2010; Lim et al., 2012) and later to lim-
bic, and ultimately to neocortical regions, such as the precuneus,
middle frontal gyrus, and posterior cingulate gyrus. The severity
of this atrophy, at least in the medial temporal regions, corre-
lates with the severity of underlying neuropathological changes
seen on postmortem studies (Echávarri et al., 2011). The second
premise is that, despite most volumetric methods focus on the
hippocampus and disregard the parahippocampal gyrus, many
studies have shown that parahippocampal atrophy is as good indi-
cator of AD as the hippocampus atrophy is (Nestor et al., 2008;
Burgmans et al., 2011; Smith et al., 2012; Zarei et al., 2012). Thus,
the entorinal cortex, the hippocampus, and the parahippocampal
gyrus may be considered as the “epicentrum” of the neurodegen-
erative process. Therefore, in order to pick up the disease early we
do not need to find out the volume of the whole hippocampus but
detect atrophy at “the point” where the pathology is visible first.
THE SLICE SELECTED
Functionally, the hippocampus can be segmented into three
distinct anatomical and functional subregions (head, body,
and tail), according to the morphology and relative connec-
tivity with prefrontal cortex (PFC), posterior cingulate cortex
(PCC), and thalamus, respectively. The AD group show stronger
hippocampus–PFC and weaker hippocampus–PCC functional
FIGURE 2 | Example of the Medial Temporal Atrophy index (MTAi) in a
patient with mild AD. The three areas were traced manually on each
hemisphere using the software for visualizing radiological images IMPAX.
The data needed to compute the index are displayed automatically. We have
underlined the different areas in colors as in Figure 1. The MTAi in the right
hemisphere is: rMTAi = (326.5 − 201.4) ×10/189.7 = 6.59. The MTAi in the
left hemisphere is: lMTAi = (326.5 − 224.0) ×10/175.2 = 5.85. Note how in
spite of the coincidence of this case with exactly the same medial temporal
region (A and A’) in both hemispheres, the right MTAi is clearly higher than
the left MTAi. Indeed when we calculate the Index of Asymmetry (IA), it is
higher than 3: IA = (5, 85 − 6.59)/(5, 85 + 6.59) ×100 = −5,15%.
Table 1 | Mean of the mean Medial Temporal Atrophy index (mMTAi)
and Index of Asymmetry (IA) values in short series of patients with
MCI (3), mild AD (3), moderate AD (3), severe AD (3), FTLD -not
staged- (3), LBD -not staged- (3) and 5 healthy controls. Values are
merely illustrative -not informative-.
Mean mMTAi Mean AI
Healthy control 2, 4 1, 8
MCI 3, 1 2, 4
Mild AD 4, 6 2, 6
Moderate AD 5, 2 2, 8
Severe AD 5, 8 3, 4
FTLD 3, 8 8, 2
DLB 2, 7 3, 7
connectivity, the magnitudes of which correlate with cognitive
performance (Convit et al., 2000; Dickerson et al., 2011; Libby
et al., 2012). In line with this fact and in order to assess the
body of the hippocampus we have taken the coronal section
passing through the interpeduncular fossa where the body of
the hippocampus can be clearly viewed. However, this index
might be performed on any other coronal slide where the MTL
structures are viewed.
THE AREAS SELECTED
Age-associated differences are detected in theMTL (Parnetti et al.,
1996; Jack et al., 1997; Apostolova et al., 2012; Leung et al., 2013)
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with an acceleration of MTA starting around 72 years of age in
healthy people (Jack et al., 1997). However, these changes are
modest and their rate of progression over time is relatively slow
with a mean rate of about 1.6% per year (Leung et al., 2013).
Accelerated MTA is a consistent finding in AD and MCI with
rates of about 2.8% in stable MCI, 3.7% in MCI transition-
ing to AD (MCI progressors), and up to 4.0% in AD (Kesslak
et al., 1991; Parnetti et al., 1996; Jack et al., 1997; Bouwman
et al., 2007; Eckerstrom et al., 2010; Jack et al., 2010; Apostolova
et al., 2012; Ewers et al., 2012; Leung et al., 2013; Heister et al.).
Frontotemporal dementia may also lead to MTA, but in a dif-
ferent pattern: frontotemporal dementia and semantic demen-
tia show atrophy in the anterior portion of the hippocampus,
and in semantic dementia the atrophy is asymmetrical, with
the left hippocampus being affected more severely. No signifi-
cant hippocampal atrophy is detected in non-fluent progressive
aphasia (Barber et al., 1999; Schacter and Wagner, 1999; Chan
et al., 2001; van de Pol et al., 2006). Other diseases such as
dementia with Lewy bodies do not show MTA or it is much
milder (Hashimoto et al., 1998; Whitwell et al., 2007; Chou et al.,
2010).
In contrast to MTA, ventricular enlargement (body of lateral
ventricles) in old people lacks specificity representing a measure
of global brain atrophy due to aging or any neurodegenerative
disorder. Global ventricular enlargement correlates with decline
in cognitive performance and with cerebrospinal fluid pathologic
markers of AD (Thompson et al., 2004; Apostolova et al., 2010).
Absolute ventricular volumes and ventricular enlargement are
greater in subjects with AD and MCI compared to age-matched
controls. Ventricular enlargement also demonstrated sensitivity
to disease progression by way of discriminating between sub-
jects with stable MCI and those that progressed to AD (Nestor
et al., 2008). However, it is important to note that all these studies
were made using absolute ventricular volumes, without differ-
entiation among the different portions of the lateral ventricles,
while the lateral (temporal) horns are the portion contributing
most to the ventricular enlargement in early AD (Giesel et al.,
2006). It is well-known that enlargement of lateral ventricles is
a measure of unspecific global brain atrophy since it is strongly
associated both with aging in healthy and with neurodegeneration
(Apostolova et al., 2012). Almost any neurodegenerative disorder
affecting the brain hemispheres leads to some degree of ven-
tricular enlargement, including Parkinson’s disease (Meyer et al.,
2007; Apostolova et al., 2010; Dalaker et al., 2011), Lewy-Bodies
Dementia (Meyer et al., 2007), Frontotemporal Lobe Dementia
(Galton et al., 2001; Gordon et al., 2010), and Corticobasal
Degeneration (Hauser et al., 1996) and so do some psychiatric
conditions (Swayze et al., 1990; Mathalon et al., 2001). Thus, it
would be interesting to compare the extent of atrophy in the MTL
with the extent of global brain atrophy (Table 1).
THE RATIO
This index reflects the rate of atrophy in the MTL—that is a value
rather specific of AD since its early stages—in relation to the
global unspecific atrophy represented by ventricular enlargement.
Thus, it is a measure estimative of the contribution of the atrophy
in the MTL to the whole brain atrophy.
ADVANTAGES AND LIMITATIONS OF THE MTA INDEX
From the clinician’s point of view, the MTA index has the
following advantages over other methods: (1) Measurement and
scoring of MTA index is objective and reliable, providing a
distinct advantage over visual techniques. (2) Volumetric mea-
surements require the use of special software, and much greater
technical stringency in the acquisition of the MRI scans and are
far more prone to a variety of measurement errors. Delineating
the areas needed for calculating the MTA index is fast and easy;
little training is needed. Therefore, it can be implemented for
daily clinical practice using basic neuroimaging facilities currently
available inmost hospitals with busy clinical settings. (3) An addi-
tional advantage of using MTA index over volumetric measures
is that regional brain volumes are variable across individuals and
need to be normalized by conversion to a ratio of the absolute vol-
umes to intracranial volume, whereas the MTA index has built-in
normalization and thus avoids multiplicative errors inherent in
using ratios of two quantitative variables. (4) The same way, as
aging affects both the hippocampus and lateral ventricles inde-
pendent of AD pathology, aging should be included as covariate
inmethods providing absolute volumes or scores. TheMTA index
is an “intra-patient” ratio comparing the MTL and lateral ventri-
cles, so it will probably not need cut-off scores adjusted by age. For
the yearly rate of MTA and the yearly rate of relative MTA, nor-
malization is not necessary neither because each subject serves as
their own control.
On the other hand, the main limitation of the MTA index is
that scoring is based on measurements performed on a single
coronal slice, thereby providing a limited perspective of overall
brain pathology. It is also expected that other conditions affecting
the ventricular morphology, such as hydrocephalus, will probably
alter the interpretation of the MTAi in these cases.
This paper is a methodological description only. Cut-off scores
have to be calculated and its use as a parameter for diagnosing AD
in research and clinical practice has to be validated. Particularly,
prospective studies are needed to assess the usefulness of MTA
index in the diagnosis of early AD, in tracking the progression of
AD and in the differential diagnosis of AD with other dementias.
CONCLUSIONS
We report a new, manual method for assessing medial temporal
lobe atrophy (MTA) that is objective and easy to apply using clin-
ically available neuroimaging. It may have some advantages over
visual and volumetric methods that still need to be evaluated.
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